Please login to the form below

Not currently logged in

Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer

Decision follows mixed results from the phase 3 ACIS study

Johnson & Johnson’s (J&J) pharma division Janssen has announced that it will not pursue regulatory submissions for a combination of its androgen receptor inhibitor Erleada and hormonal therapy Zytiga in prostate cancer.

Specifically, Janssen will not pursue regulatory approval based on the phase 3 ACIS study, which evaluated Erleada (apalutamide) and Zytiga (abiraterone acetate) plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

The ACIS study met its primary endpoint of radiographic progression-free survival (rPFS), with a 31% reduction in the risk of radiographic progression or death in these patients.

The primary efficacy analysis showed that median rPFS was extended by six months in patients treated with the Erleada/Zytiga combination compared with patients in the control arm receiving Zytiga plus prednisone alone.

A prespecified analysis also showed that patients aged 75 years or older and those with visceral metastasis, luminal type in PAM50 test and tumours with average or high androgen receptor (AR) activity may derive ‘clinical benefit’ from the Erleada/Zytiga combination treatment, according to Janssen.

However, Janssen disclosed yesterday that the Erleada/Zytiga combination treatment did not demonstrate significant benefit over Zytiga plus prednisone in key secondary endpoints, including overall survival (OS).

“Safety results from ACIS were consistent with prior studies of Erleada and Zytiga plus prednisone, with no new safety signals observed,” said Kiran Patel, vice president, clinical development, solid tumours, Janseen Research & Development.

“The study also generated valuable scientific outcomes and insights in subgroups of patients with luminal type in PAM50 test and tumours with average or high androgen receptor activity (molecular signatures of hormone sensitivity), which warrant further investigation,” he added.

In February, Janssen revealed additional results for Erleada, this time in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Final analysis from the phase 3 TITAN study, which included nearly four years of median follow-up, demonstrated a 35% reduction in the risk of death in mHSPC patients receiving Erleada plus ADT compared to ADT alone.

In the EU, Erleada is approved for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).

Article by
Lucy Parsons

20th April 2021

From: Research



Subscribe to our email news alerts


Add my company
Origins - The Patient Focused Specialists

Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...